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Abstract
Microbial RNases along with such animal RNases as onconase and BS-RNase are a promising basis for developing new antitumor
drugs. We have shown that the Bacillus intermedius RNase (binase) induces selective apoptosis of transformed myeloid cells. It attacks
artiﬁcially expressing activated c-Kit myeloid progenitor FDC cells and chronic myelogenous leukemia cells K562. Binase did not induce
apoptosis in leukocytes of healthy donors and in normal myeloid progenitor cells. The inability of binase to initiate expression of acti-
vation markers CD69 and IFN-c in CD4+ and CD8+ T-lymphocytes testiﬁes that enzyme is devoid of superantigenic properties. Alto-
gether, these results demonstrate that binase possesses therapeutic opportunities for treatment of genotyped human neoplasms expressing
activated kit.
 2007 Elsevier Inc. All rights reserved.
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Ribonucleases (RNases) are involved in control of gene
expression, host defence and physiological cell death path-
ways. In some cases, RNases selectively attack malignant
cells, triggering apoptotic response, and therefore are con-
sidered as alternative chemotherapeutic drugs [1–3].
Onconase, a frog (Rana pipiens) RNase, has reached phase
III of clinical trials [4]. Recent data on the cytotoxic eﬀects
of microbial RNases, such as the Bacillus intermedius
RNase (binase) [5], Streptomyces aureofaciens RNase Sa3
[6], and 5K cationic mutant of RNase Sa [7,8] suggest that
bacterial RNases are a promising basis for developing new
antitumor drugs. In order to be eﬀective therapeutics,
RNases have to aﬀect selectively certain targets in cancer
cells, which distinguish the latter from healthy ones, and
they should not cause undesirable immune reactions. Thus,
onconase does not exhibit strong immunotoxicity, it
cleaves tRNA and selectively inhibits growth of ras-
expressing tumor cells [9].
Binase is a highly cationic guanyl-speciﬁc RNase that
catalyzes cleavage of RNA without a need for metal ions
and cofactors. The structure of crystalline binase is known
at a resolution of 1.65 A˚ [10]. We have shown that ras-
expressing ﬁbroblasts are more susceptible to binase than
normal cells [5]. In addition to this important target,
mutated in at least 25% of patients with oncological dis-
eases [11], an attractive group of target proteins are the
kinases [12]. Binase has no eﬀect on proliferation of v-
fms- or v-src-transformed ﬁbroblasts, expressing receptor
and non-receptor tyrosine kinases, respectively [5]. Is Kit,
which is an another receptor tyrosine kinase, able to cause
the selectivity of the binase eﬀect? Overexpression or con-
stitutive activation of Kit by mutations have been associ-
ated with various malignancies (gastrointestinal stromal
cell tumors, mastocytosis, certain forms of germ cell
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